KRAS: Old Target, New Hope

Molecular Resistance Mechanisms to EGFR, ALK, and ROS1 TKIs

Approval of Combination Ipilimumab and Nivolumab for Mesothelioma: What Happens Now?

Mutation or Amplification: Who MET the Expectations?

RET Therapy for NSCLC, a New Generation of Inhibitors

The Multitude of Options for First-Line Therapy for EGFR-Mutated Lung Cancer

The Current Role of Combination Maintenance Therapy (Pemetrexed and Bevacizumab) in the Era of Immunotherapy

Dr. Kazuhiko Nakagawa Discusses RELAY Study Data, Implications for Practice

Lorlatinib in ROS1-Positive NSCLC: A Review of Recent Data

Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in NSCLC

Insight Into Genomic Correlates of PD-L1 Expression and the Response to Immune Checkpoint Blockade

Histologic Transformation From NSCLC to SCLC: A Mechanism of Resistance to Osimertinib and Other Agents Targeting EGFR Mutations